12:00 AM
 | 
Dec 16, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Veliparib: Phase II data

Researchers at the University of California, San Francisco and colleagues said a veliparib-containing regimen "graduated" from the open-label Phase II I-SPY 2 trial based on having a high probability of success in patients with triple-negative breast cancer (TNBC) in a Phase III trial. The trial is designed to rapidly and inexpensively develop data to support small Phase III trials of new neoadjuvant therapies for locally advanced breast cancer or to help companies quickly kill ineffective candidates. I-SPY 2 involves an adaptive trial design based on Bayesian predictive probability that a regimen will be statistically superior to standard therapy in an equally randomized 300-patient confirmatory trial.

In patients with TNBC, veliparib plus carboplatin and paclitaxel followed by anthracycline-based chemotherapy prior to surgery led to an...

Read the full 612 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >